Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Proteostasis Therapeutics (PTI) Share Price

Press coverage about Proteostasis Therapeutics (NASDAQ:PTI) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.148480264474 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Proteostasis Therapeutics (NASDAQ:PTI) traded up 1.60% during trading on Tuesday, reaching $1.91. The company had a trading volume of 35,333 shares. The firm’s market capitalization is $47.94 million. Proteostasis Therapeutics has a 12 month low of $1.71 and a 12 month high of $16.67. The stock has a 50 day moving average price of $2.10 and a 200 day moving average price of $5.21.

Several equities analysts recently weighed in on the company. Leerink Swann reiterated an “outperform” rating and set a $9.00 target price (down from $17.00) on shares of Proteostasis Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research upgraded Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Proteostasis Therapeutics in a research report on Friday, June 30th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Proteostasis Therapeutics (PTI) Share Price” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/09/19/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-proteostasis-therapeutics-pti-share-price.html.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply